The physiological role of ovarian progesterone in reproduction and the medical uses of synthetic progestins and antiprogestins are briefly reviewed. Although a number of progestins are in wide use, the search continues for better analogues that display fewer of the unwanted effects of the present compounds. The one antiprogestin approved for human use to date, RU486, exhibits considerable antiglucocortoid activity
The classical bioassays currently in use for the development of these steroid analogues depend upon in vivo progestin effects. However, progestins induce measurable responses in several cell culture systems that could be used as alternative bioassays. Rabbit uterine stromal cells in primary culture are especially suitable for such use. Addition of progesterone to these cultures stimulates synthesis of a 42 kilodalton (42kD) protein that appears in the medium. The 42kD protein response is specific for a progesterone receptor-mediated event and it can be blocked by known progestins. Using this culture system as a bioassay, one rabbit yields enough cells to measure the effect of 30 test doses in triplicate. Thus, a culture system is described that could substitute for current in vivo bioassays. This culture bioassay would allow large scale screening for potential progestin or antiprogestin activity.
DickeyR.P., and StoneS.C. (1976). Progestational potency of oral contraceptives.American Journal of Obstetrics and Gynecology47, 106–111.
2.
JonesR.C., and EdgrenR.A. (1973). The effects of various steroids on vaginal histology in the rat.Fertility and Sterility24, 284–291.
3.
PhillipsA., HahnD.W., KlimekS., and McGuireJ.L. (1986). Comprehensive comparison of the potencies and activities of progestagens used in contraceptives.Contraception36, 181–192.
4.
OjasooT., and RaynaudJ.P. (1983). Receptor binding profiles of progestins. In Steroids and Endometrial Cancer (ed. JasonniV.M., NenciI., FlamigniC.), pp. 11–28. New York: Raven Press.
5.
SwyerG.I.M., and LittleV. (1968). Clinical assessment of relative potency of progestagens.Journal of Reproduction and Fertility, Suppl. 5, 63–68.
6.
HeaneyR.P. (1976). Estrogens and postmenopausal osteoporosis.Clinical Obstetrics and Gynecology19, 791–803.
7.
AitkenJ.M. (1976). Osteoporosis and its relation to estrogen deficiency. In The Management of the Menopause and Postmenopausal Years (ed. CampbellS.), pp. 225–231. Lancaster, UK: MTP Press.
8.
NachtigallL.E., NachtigallR.H., NachtigallR.D., and BeckmanE.M. (1979). Estrogen replacement therapy. I. A 10-year prospective study in the relationship to osteoporosis.Obstetrics & Gynecology53, 277–281.
9.
GambrelR.D. (1987). Use of progestogen therapy.American Journal of Obstetrics and Gynecology156, 1304–1313.
10.
RyanK.J. (1976). Estrogens and atherosclerosis.Clinical Obstetrics and Gynecology19, 805–823.
11.
AlbersJ.J., CheungM.C., and HazzardW.R. (1978). High-density lipoproteins in myocardial infarction survivors.Metabolism27, 479–485.
12.
HirvonenE., MalkonenM., and ManninenV. (1981). Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.New England Journal of Medicine304, 560–563.
13.
RunnebaumB., and RabeT. (1987). New progestagens in oral contraceptives.American Journal of Obstetrics and Gynecology157, 1059–1063.
14.
RunnebaumB., and RabeT. (1989). New progestins in hormonal contraceptives.Archives of Gynecology and Obstetrics245, 1000–1005.
15.
BaulieuE. (1986). Fertility control in women: results with RU486 by the end of 1985.Journal of Steroid Biochemistry25, 847–851.
16.
BaulieuE.E. (1989). Contragestion and other clinical applications of RU486, an anti-progesterone at the receptor.Science245, 1351–1357.
17.
NeefG., BeierS., ElgerW., HendersonD., and WiechertR. (1984). New steroids with antiprogestational and antiglucocorticoid activities.Steroids44, 349–372.
18.
ElgerW., BeierS., ChwaliszK., FahrichM., DasanS.H., HendersonD., NeefeG., and RohdeR. (1986). Studies on the mechanisms of action of progesterone antagonists.Journal of Steroid Biochemistry25, 835–845.
19.
MaudelondeT., RomieuG., UlmannA., PujolH., GrenierJ., KhalafS., CavalieG., and RochefortH. (1987). First clinical trial on the use of the antiprogestin RU486 in advanced breast cancer. In Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)Steroidal Agents (ed. KlijnJ.G.M., ParidaensR., FoekensJ.A.), pp. 55–60. New York: Raven Press.
20.
HissomJ.R., BowdenR.T., and MooreM.R. (1989). Effects of progestins, estrogens and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D.Endocrinology125, 418–423.
21.
BakkerG.H., Setyono-HanB., PortengenH., De-JongF.H., FoekensJ.A., and KlijnJ.G. (1989). Endocrine and antitumour effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.Endocrinology125, 1593–1598.
22.
MichnaH., SchneiderM.R., NishinoY., & el-EtrebyM.F. (1989). Antitumour activity of the antiprogestins ZK98.299 and RU38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.Breast Cancer Research and Treatment14, 275–288.
23.
WelchR.M., LevinW., and ConneyA.H. (1969). Estrogenic action of DDT and its analogs.Toxicology and Applied Pharmacology14, 358–367.
24.
O'LearyJ.A., DaviesJ.E., and FeldmanM. (1970). Spontaneous abortion and human pesticide residues of DDT and DDE.American Journal of Obstetrics and Gynecology108, 1291–1292.
25.
BulgerW.H., and KupferD. (1985). Estrogenic action of DDT analogs.American Journal of Industrial Medicine4, 163–173.
26.
PakrashiA., and BasakB. (1976). Abortifacient effect of steroids from Ananas comosus and their analogues on mice.Journal of Reproduction and Fertility46, 461–462.
27.
RobertsC.J., and LoweC.R. (1978). Where have all the conceptions gone?Lanceti, 498–499.
28.
MosherW.D. (1980). Reproductive impairments among currently married couples: United States, 1976. In Advance Data from Vital and Health Statistics of the National Center for Health Statistics55, 1–11. US Department of Health, Education and Welfare.
29.
PlacekP.J., and CynamonM.L. (1980). NCHS Data on Voluntary and Involuntary Infertility, with Synthetic Estimation Application. Working Paper Series, No. 1, October 1980. Division of Vital Statistics, US Department of Health and Human Services.
30.
ClaubergC. (1930). Zur physiologie und pathologie der sexualhormone im besonderen des hormons des corpus luteum. I. Mitteilung: der biolgische test für das luteohormon (das spezifische hormon des corpus luteum) am infatilen kaninchen.Zentralbl Gynakologie54, 2757–2770.
31.
McPhailM.K. (1934). The assay of progestin.Journal of Physiology (London)83, 145–156.
32.
AstwoodE.B. (1939). An assay method for progesterone based upon the decidual cell reaction in the rat.Journal of Endocrinology1, 49–55.
33.
DeckersG.H.J., GeelenJ.A.A., KloosterboerH.J., & van den HeuvelM.J. (1990). Endocrine profiles of two novel antiprogestagens: Org 31710 and Org 31806.72nd Annual Meeting of the Endocrine Society, Atlanta, June 1990, Abstract No. 136.
O'MalleyB.W., TsaiM.J., and SchraderW.T. (1983). Structural consideration for the action of steroid hormones in eucaryotic cells. In Steroid Hormone Receptors (ed. ErikssonH., GustafssonJ.), pp. 307–328. New York: Elsevier.
36.
BaillyA., LePageC., RauchM., and MilgromE. (1986). Sequence-specific DNA binding of the progesterone receptor to the uteroglobin gene: effects of hormone, antihormone and receptor phosphorylation.EMBO Journal5, 3235–3242.
37.
BullockD.W., LambD.J., RiderB.C., and KimaP.E. (1987). The rabbit progesterone receptor and uteroglobin gene expression. In Cell and Molecular Biology of the Uterus (ed. LeavittW.W.), pp. 79–97. New York: Plenum Press.
38.
BoomsmaR.A., and VerhageH.G. (1987). Detection of a progesterone-dependent secretory protein synthesised by cat endometrium.Biology of Reproduction37, 117–126.
39.
BellS.C. (1986). Secretory endometrial and decidual proteins: studies and clinical significance of a maternally derived group of pregnancy-associated serum proteins.Human Reproduction1, 129–143.
40.
BellS.C., PatelS.R., KirwanP.H., and DrifeJ.O. (1986). Protein synthesis and secretion by the human endometrium during the menstrual cycle and the effect of progesterone in vitro.Journal of Reproduction and Fertility77, 221–231.
41.
AlpinJ.D. (1989). Cellular biochemistry of the endometrium. In Biology of the Uterus, 2nd edn (ed. WynnR.M., JollieW.P.), pp. 89–129. New York: Plenum Press.
42.
HeffnerL.J., IddendenD.A., and LyttleC.R. (1986). Electrophoretic analyses of secreted human endometrial proteins: identification and characterization of luteal phase prolactin.Journal of Clinical Endocrinology and Metabolism62, 1288–1295.
43.
HolinkaC.F., and GurpideE. (1984). Diamine oxidase activity in human decidua and endometrium.American Journal of Obstetrics and Gynecology150, 359–363.
44.
TsengL., and GurpideE. (1975). Induction of human endometrial estradiol dehydrogenase by progestins.Endocrinology97, 825–833.
45.
TsengL., and GurpideE. (1979). Stimulation of various 17β- and 20α-hydroxysteroid dehydrogenase activities by progestins in human endometrium.Endocrinology104, 1745–1748.
46.
TsengL., MazellaJ., and SunB. (1986). Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU486.Endocrinology118, 1312–1318.
47.
CasslénB.G., Siler-KhodrT.M., and HarperM.J.K. (1990). Progesterone regulation of prolactin release from human endometrial stromal cells in culture: potential bioassay for progestational activity.Acta Endocrinologica (Copenhagen)122, 137–144.
48.
IrwinJ.C., KirkD., KingR.J., QuigleyM.M., and GwatkinR.B. (1989). Hormonal regulation of human endometrial stromal cells in culture: an in vitro model for decidualization.Fertility and Sterility52, 761–768.
49.
GroyerA., LeBoucY., HoabI., RadanyiC., RenoirJ., RobleP., and BaulieuE. (1985). Chick oviduct glucocorticoid receptor: specific binding of the synthetic steroid RU486 and immunological studies with antibodies to chick oviduct progesterone receptor.European Journal of Biochemistry149, 445–451.
50.
HorwitzK.B., and FreidenbergG.R. (1985). Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47Dco human breast cancer cells by progestins: implications for endocrine therapies.Cancer Research45, 167–173.
51.
MurphyL.J., SutherlandR.L., and LazarusL. (1985). Regulation of growth hormone and epidermal growth factor receptors by progestins in breast cancer cells.Biochemistry and Biophysics Research Communications131, 767–773.
52.
MurphyL.J., MurphyL.C., SteadB., SutherlandR.L., and LazarusL. (1986). Modulation of lactogenic receptors by progestins in cultured human breast cancer cells.Journal of Clinical Endocrinology and Metabolism62, 280–287.
53.
ChenG., HuangJ.R., MazellaJ., and TsengL. (1989). Long-term effects of progestin and RU486 on prolactin production and synthesis in human endometrial stromal cells.Human Reproduction4, 355–358.
54.
WahlströmT., & SeppäläM. (1984). PP12 is induced in the endometrium by progesterone.Fertility and Sterility41, 781–784.
55.
TsengL., MalbonC.C., LaneB., KaplanC., MazellaJ., DahlerH., and TsengA. (1987). Progestin-dependent effect of forskolin on human endometrial aromatase activity.Human Reproduction2, 371–377.
56.
MaudelondeT., and RochefortH. (1987). A 51K progestin-regulated protein secreted by human endometrial cells in primary culture.Journal of Clinical Endocrinology and Metabolism64, 1294–1301.
57.
RajkumarK., BigsbyR., LiebermanR., and GerschensonL.E. (1983). Effect of progesterone and 17β-estradiol on the production of uteroglobin by cultured rabbit uterine epithelial cells.Endocrinology112, 1499–1505.
58.
KieselL., HelmK., BergesK., MaierC., RabeT., and RunnebaumB. (1987). Contraceptive progestins and gonadotropin secretion in vitro.Journal of Steroid Biochemistry27, 995–1002.
59.
TsengJ.K., SunB., and TsengL. (1988). The effect of progestin on rabbit endometrial aromatase activity.Journal of Steroid Biochemistry29, 9–13.
60.
BigsbyR.M. (1986). Progesterone induces a secretory protein in cultured rabbit endometrial stromal cells.Journal of Steroid Biochemistry35, 937–942.
61.
AdamsE.F., ColdhamN.G., and JamesV.H.T. (1988). Steroidal regulation of oestradiol-17β dehydrogenase activity of the human breast cancer cell line MCF-7.Journal of Endocrinology118, 149–154.
62.
KontulaK., JänneO., VihkoR., de JagerE., de VisserJ., and ZeelenR. (1975). Progesterone-binding proteins: in vitro binding and biological activity of different steroidal ligands.Acta Endocrinologica78, 574–592.
63.
SamuelsH.H., and TomkinsG.M. (1970). Relation of steroid structure to enzyme induction in hepatoma tissue culture cells.Journal of Molecular Biology52, 57–74.
64.
RousseauG.G., and SchmitJ.P. (1977). Structure-activity relationships for glucocorticoids. I. Determination of receptor binding and biological activity.Journal of Steroid Biochemistry8, 911–919.
65.
HorwitzK.B., KosekiY., and McGuireW.L. (1978). Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.Endocrinology103, 1742–1751.
66.
KayeA.M., ShinkarenkoL., WaismanA., VictorT., and DeganiH. (1989). Estradiol induction of accelerated energy metabolism in prepuberal rat uteri in vitro: mRNA hybridization and [13C]NMR studies.Journal of Steroid Biochemistry34, 289–292.
67.
VeithF.O., CaponyF., GarciaM., ChantelardJ., PujolH., VeithF., ZajdelaA., and RochefortH. (1983). Release of estrogen-induced glycoprotein with a molecular weight of 52,000 by breast cancer cells in primary culture.Cancer Research43, 1861–1868.
